Safety, Attenuation and Immunogenicity of GAP3KO Administered Via A Stephensi Mosquitoes

Inclusion Criteria: * Good general health * No hematologic, hepatic, or renal disease * Weight greater than 50 kg * Assessment of Understanding completed and passed prior to enrollment * Availability and reliable access to trial center * Females must use two forms of pregnancy prevention Exclusion Criteria: * Recent (within 6 months) or planned travel to malaria endemic area * History of confirmed malaria diagnosis * Anticipated use of the following: * Investigational malaria vaccine at any time * Malaria chemoprophylaxis within 6 months * Chronic systemic immunosuppressive medications within 6 months * Blood products or immunoglobulin within 120 days * Systemic antibiotics with antimalarial effects within 30 days * Investigational product or vaccine within 30 days * Live vaccine within 28 days; killed vaccine within 14 days of GAP3KO * Medications known to significantly interact with chloroquine or Malarone * History of: * Sickle cell trait or other hemoglobinopathies * Splenectomy or functional asplenia * Systemic anaphylaxis * Severe allergic reaction to mosquito bites or malaria treatment drugs * History of chronic or active neurologic disease * Cardiac disease or stroke * Clinically significant medical condition, abnormal lab results * Clinically significant abnormal ECG * Moderate or high risk for coronary heart disease * Acute illness * Pregnant or nursing female * HIV, Hepatitis B, or Hepatitis C * Psychiatric condition that precludes compliance with the protocol * Suspected or known alcohol or drug abuse * Staff with direct involvement in conduct of the study or GAP activities